Importance of early diagnosis in patients with irritable bowel syndrome

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 102-111

  Halpert, Albena D ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Diagnostic tests; Early diagnosis; Functional gastrointestinal disorders; Irritable bowel syndrome; Quality of life

Indexed keywords

BIOLOGICAL MARKER;

CELIAC DISEASE; COMORBIDITY; CONSTIPATION; DELAYED DIAGNOSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DYSPEPSIA; EARLY DIAGNOSIS; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; HELP SEEKING BEHAVIOR; HUMAN; IRRITABLE COLON; PHYSICIAN ATTITUDE; PREDICTIVE VALUE; PREVALENCE; REVIEW; SYMPTOMATOLOGY; DIFFERENTIAL DIAGNOSIS; HEALTH SURVEY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; QUALITY OF LIFE; TIME;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HEALTH STATUS INDICATORS; HUMANS; IRRITABLE BOWEL SYNDROME; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; TIME FACTORS;

EID: 77950353573     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2127     Document Type: Review

References (72)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-1491.
2. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97(8):1910-1915.
3. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidencebased position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.
4. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365-1375.
5. Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(2):117-130.
6. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11(3):3-15.
7. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007;26(6):953-961.
8. Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128(3):580-589.
9. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut. 2001;48(1):14-19.
10. Camilleri M. Evolving concepts of the pathogenesis of irritable bowel syndrome: to treat the brain or the gut? J Pediatr Gastroenterol Nutr. 2009;48(suppl 2):S46-S48.
11. Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol. 2006;41(3):217-222.
12. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-811.
13. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292(7):852-858.
14. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24-33.
15. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557-563.
16. Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(8):834-842.
17. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108-2131.
18. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association; 2001.
19. Cash BD, Chey WD. Irritable bowel syndrome-an evidence-based approach to diagnosis. Aliment Pharmacol Ther. 2004;19(12):1235-1245.
20. Hasler WL, Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(8):997-1005.
21. Doshi M, Heaton KW. Irritable bowel syndrome in patients discharged from surgical wards with non-specific abdominal pain. Br J Surg. 1994;81(8):1216-1218.
22. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126(7):1665-1673.
23. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-S26.
24. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-1580.
25. International Foundation for Functional Gastrointestinal Disorders. IBS in the Real World survey. Summary findings. International Foundation for Functional Gastrointestinal Disorders. http://aboutconstipation.org/pdfs/IBSRealWorld.pdf. Accessed September 1, 2009.
26. Drossman DA, Li Z, Leserman J, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology. 1996;110(4):999-1007.
27. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-550.
28. Bertram S, Kurland M, Lydick E, et al. The patient's perspective of irritable bowel syndrome. J Fam Pract. 2001;50(6):521-525.
29. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171-1185.
30. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-660.
31. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol. 1999;94(10):2912-2917.
32. Heaton KW, Thompson WG. Irritable Bowel Syndrome. Oxford, UK: Health Press; 1999.
33. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-654.
34. Spiegel BM. Do physicians follow evidence-based guidelines in the diagnostic work-up of IBS? Nat Clin Pract Gastroenterol Hepatol. 2007;4(6):296-297.
35. Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003;98(11):2454-2459.
36. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122(4):1140-1156.
37. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep. 2005;7(4):264-271.
38. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32-39.
39. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97(11):2812-2819.
40. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227.
41. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008;358(16):1692-1699.
42. Lacy BE, Rosemore J, Robertson D, et al. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol. 2006;41(8):892-902.
43. Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol. 2007;102(9):1972-1982.
44. Casiday RE, Hungin AP, Cornford CS, et al. Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Fam Pract. 2009;26(1):40-47.
45. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA. 2008;300(15):1793-1805.
46. Rubin G, De WN, Meineche-Schmidt V, et al. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract. 2006;23(6):687-692.
47. Drossman DA, Talley NJ, Whitehead WE, Thompson WG, Corazziari E. Appendix B. Research Diagnostic Questions for Functional Gastrointestinal Disorders. Rome II Modular Questionnaire: Investigator and Respondent Forms. http://www.romecriteria.org/documents/Rome_II_appB.pdf. Accessed July 10, 2009.
48. Longstreth GF, Burchette RJ. Family practitioners' attitudes and knowledge about irritable bowel syndrome: effect of a trial of physician education. Fam Pract. 2003;20(6):670-674.
49. Dixon-Woods M, Critchley S. Medical and lay views of irritable bowel syndrome. Fam Pract. 2000;17(2):108-113.
50. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83(3):529-534.
51. Kettell J, Jones R, Lydeard S. Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics. Br J Gen Pract. 1992;42(364):459-461.
52. Jain AP, Gupta OP, Jajoo UN, Sidhwa HK. Clinical profile of irritable bowel syndrome at a rural based teaching hospital in central India. J Assoc Physicians India. 1991;39(5):385-386.
53. Sandler RS, Drossman DA, Nathan HP, McKee DC. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology. 1984;87(2):314-318.
54. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988;95(3):701-708.
55. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927-934.
56. Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology. 1992;102(6):1962-1967.
57. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT Jr, Schuster MM. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology. 1988;95(3):709-714.
58. Heitkemper M, Carter E, Ameen V, et al. Women with irritable bowel syndrome: differences in patients' and physicians' perceptions. Gastroenterol Nurs. 2002;25(5):192-200.
59. Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci. 2010;55(1):145-149.
60. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(2):455-459.
61. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95(4):999-1007.
62. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123(2):450-460.
63. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162-169.
64. Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51(3-4):117-126.
65. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98(6):1309-1314.
66. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133(5):1670-1689.
67. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47(4):506-513.
68. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14(10):1392-1398.
69. Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37(2):85-96.
70. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19(7):567-574.
71. Hille A, Schmidt-Giese E, Hermann RM, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol. 2008;43(1):52-58.
72. Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut. 2009;58(12):1571-1575.